


# NEWS



**Preprint portals:**  
Prepublication sites  
for biomedicine gather  
support



**Age-old problems:**  
The hurdles in drug  
development to  
combat aging



**Life-saving food:**  
Battles loom over  
insurance payments  
for medical food

## Japan to offer fast-track approval path for stem cell therapies


TOKYO — A retooling of Japan's drug authorization framework, on its way to becoming law, could produce the world's fastest approval process specifically designed for regenerative medicine. "I don't know of any other countries that have broken out with a separate and novel system" for cellular therapies, says University College London regenerative medicine expert Chris Mason, who recently met with Japanese policymakers to discuss the law.

Japan has recently been trying to shake its 'drug lag,' a term used to describe its historically slow review process that sometimes translates into therapies reaching the market well after they have received the green light elsewhere. But the country is now ready to speed the translation of regenerative medicine to the bedside.

The move comes in response to the potential offered by its homegrown induced pluripotent stem (iPS) cell technology, which netted Shinya Yamanaka, of the University of Kyoto, last year's Nobel Prize in Medicine or Physiology. The government already flooded the field with more than 20 billion yen (\$206 million) in a supplementary budget announced earlier this year, and it's expected to allocate another 90 billion yen into the sector over the coming decade.

Under the Pharmaceutical Affairs Law as it currently stands, regenerative therapies, like small-molecule drugs, must undergo three phases of costly and cumbersome clinical trials to get approval by Japan's Pharmaceutical and Medical Devices Agency.

The proposed amendments to the pharmaceutical law will create a new, separate approval channel for regenerative medicine. Rather than using phased clinical trials, companies will have to demonstrate efficacy in pilot studies of as few as ten patients in one study, if the change is dramatic enough, or a few hundred when improvement is more marginal. According to Toshio Miyata, deputy director of the Evaluation and Licensing Division at the Pharmaceutical and Food Safety Bureau in Tokyo, if efficacy can be "surmised," the treatment will be approved for marketing. At that stage, the treatment could be approved for commercial use and, crucially for such expensive treatments, for national insurance coverage.



Matti Hansen

**Land of the rising stem cell:** Regenerative therapies gain accelerated path to the Japanese market.

### Phased out

With the bar for regenerative therapies dramatically lowered by requiring only limited safety and efficacy data—and essentially doing away with the need for high-powered phase 3 trials—the amendments' architects say it will be possible to get a stem cell treatment to the market in just three years, rather than the typical six or more. The law should also give local producers of regenerative medicine an edge even over those selling stem cell therapies in South Korea, where an accelerated system has helped companies get more stem cell treatments on the market than any other country (see *Nat. Med.* 18, 329, 2012). "It's bold," says Yoshihide Esaki, director of Bio-Industry Division, a bureau of the Ministry of Economy, Trade and Industry based in Tokyo, which promoted legislation calling for the update.

Following approval, there will be a post-market surveillance period of five to seven years, after which the treatment will be evaluated again for safety and efficacy. Every patient must be entered in a registry during that period, says Miyata. If the therapies prove ineffective or unsafe, approval can be withdrawn.

Doug Sipp worries whether post-market

surveillance will turn up relevant data. Sipp, who studies regulatory issues related to stem cells at the RIKEN Center for Developmental Biology in Kobe, Japan, says that making people who receive the therapies during this period cough up even the 30% co-pay generally required under Japan's national insurance plan "will essentially be asking patients to pay for the privilege of serving as the subjects of medical experiments." And since the patients are paying, the studies cannot be randomized or blinded. Paying patients are also more likely to experience placebo effects, Sipp warns.

"There's also the opportunity costs to patients," who might be able to find better therapies elsewhere, adds Mason. "We have to make sure these therapies are safe and effective. Otherwise these regulatory routes are going to be closed."

Despite these concerns, passage of the pre-vetted law is almost a given. Esaki says there's a 50% chance the Japanese parliament will pass the law during the current session, ending in June. If so, it would go into effect next April. If not, scientists might have to wait until November 2014 or as late as April 2015.

David Cyranoski



[FDA Home](#)<sup>3</sup> [Medical Devices](#)<sup>4</sup> [Databases](#)<sup>5</sup>

## CFR - Code of Federal Regulations Title 21

[New Search](#)


[Help](#)<sup>6</sup> | [More About 21CFR](#)<sup>7</sup>

[Code of Federal Regulations]

[Title 21, Volume 8]

[Revised as of April 1, 2014]

[CITE: 21CFR1271.15]



### TITLE 21--FOOD AND DRUGS

#### CHAPTER I--FOOD AND DRUG ADMINISTRATION

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### SUBCHAPTER L--REGULATIONS UNDER CERTAIN OTHER ACTS ADMINISTERED BY THE FOOD AND DRUG ADMINISTRATION

#### PART 1271 -- HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS

#### Subpart A--General Provisions

Sec. 1271.15 Are there any exceptions from the requirements of this part?

(a) You are not required to comply with the requirements of this part if you are an establishment that uses HCT/P's solely for nonclinical scientific or educational purposes.

(b) You are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure.

(c) You are not required to comply with the requirements of this part if you are a carrier who accepts, receives, carries, or delivers HCT/P's in the usual course of business as a carrier.

(d) You are not required to comply with the requirements of this part if you are an establishment that does not recover, screen, test, process, label, package, or distribute, but only receives or stores HCT/P's solely for implantation, transplantation, infusion, or transfer within your facility.

(e) You are not required to comply with the requirements of this part if you are an establishment that only recovers reproductive cells or tissue and immediately transfers them into a sexually intimate partner of the cell or tissue donor.


(f) You are not required to register or list your HCT/P's independently, but you must comply with all other applicable requirements in this part, if you are an individual under contract, agreement, or other arrangement with a registered establishment and engaged solely in recovering cells or tissues and sending the recovered cells or tissues to the registered establishment.

#### Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/MedicalDevices/default.htm>
5. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/default.htm>
6. </scripts/cdrh/cfdocs/search/default.cfm?FAQ=true>
7. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135680.htm>
8. [/scripts/cdrh/devicesatfda/index.cfm?Search\\_Term=Are%20there%20any%20exceptions%20from%20the%20requirements%20of%20this%20part%3F](/scripts/cdrh/devicesatfda/index.cfm?Search_Term=Are%20there%20any%20exceptions%20from%20the%20requirements%20of%20this%20part%3F)



# NEW LAW A BOOST TO STEM CELL THERAPIES IN JAPAN



There have been some new developments in Japan which could make a huge difference to regenerative medicine there and mean doctors will be able to use new treatments, including stem cell therapies, years earlier than they might have done. The Upper House of Japan's parliament has passed a new law which allows 'conditional' approval for stem cell therapies based on probable efficacy and safety in small-scale trials. This would be backed up by comprehensive studies to confirm safety and efficacy in a wider population and full approval if those trials are successful. For

patients, this means the therapies will be available far sooner and they can potentially benefit from this innovative approach to medicine earlier than would be possible in many other countries. Japan has been promoting regenerative medicine for a number of years and one of its scientists, Dr Shinya Yamanaka, received a Nobel Prize, together with Sir John Gurdon, in 2012 for his discovery that mature cells can be reprogrammed and made pluripotent – where they can become a number of different tissue types. Cardio3 BioSciences was consulted by experts from the Japanese regulatory agency in February 2013 on the content of this proposed legislation and had a chance to comment on it. It's very encouraging to see regenerative medicine gaining recognition in one of the world's biggest markets and being backed by supportive legislation to accelerate its use. Our own approach to Asia is to look to partner our technologies there when they reach a development stage providing a favourable return to our investors. Seeing more regenerative medicines making a difference to patient's lives can only benefit the field.